Clinical trials
Nasopharyngeal Carcinoma clinical trials
Below are recruiting nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 168 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04425265Recruiting
Low-temperature plasma treatment vs high-frequency cautery for recurring cancer
This trial compares two ways of surgically treating localized, recurrent nasopharyngeal cancer: a low-temperature plasma radiofrequency method versus a standard high-frequency cautery method. You might be eligible if your recurrence is limited and can be surgically removed, and you are within the allowed health and age ranges.
Guangzhou, GuangdongAges 18–70 - NCT07661771RecruitingPhase 3
Personalized radiation therapy for nasopharyngeal cancer
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
Dongguan, GuangdongAges 18–65 - NCT04436965RecruitingPhase 3
Standard nutrition support for malnourished nasopharyngeal cancer patients
This Phase 3 study tests whether giving a standard nutrition plan can improve nutritional status and outcomes in people with locally advanced nasopharyngeal cancer who are malnourished. It mainly checks whether nutrition support helps you tolerate treatment and do better over time.
Guangzhou, GuangdongAges 18–65 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06383780RecruitingPhase 3
Tislelizumab plus chemo for nasopharyngeal cancer with bone spread
This trial tests a combination of the immunotherapy drug tislelizumab with chemotherapy for people whose nasopharyngeal cancer has spread to the bones. It may be an option if you have not had prior treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT06976190RecruitingPhase 3
MRG003 plus pucotenlimab vs chemo for advanced nasopharyngeal cancer
This trial tests whether combining an experimental antibody-drug conjugate (MRG003) with an immunotherapy (pucotenlimab) works better than standard chemotherapy for people with nasopharyngeal cancer that has come back or spread. If you have tried at least one prior treatment and are generally in good health, you may be able to join.
Guangzhou, GuangdongAges 18–75 - NCT07258979RecruitingPhase 1/Phase 2
YL201 and Toripalimab with or without Cisplatin for Nasopharyngeal Cancer
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT06870435Recruiting
Screening for nasopharyngeal cancer with blood tests
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Zhuhai, GuangdongAges 30–69 - NCT06241599RecruitingPhase 2/Phase 3
AK104 with chemo for advanced nasopharyngeal cancer
This study tests if adding a new immunotherapy drug (called AK104) to standard chemotherapy can help people whose nasopharyngeal cancer has come back or spread after previous treatment. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT06438627RecruitingPhase 3
New triple therapy vs standard for advanced nasopharyngeal cancer
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
Guangzhou, GuangdongAges 18–65 - NCT07340515RecruitingPhase 3
Proton vs standard radiation for advanced nasopharyngeal cancer
This trial is testing whether a newer, more precise type of radiation (proton therapy) works better than standard radiation (IMRT) for people with advanced nasopharyngeal cancer. It also includes chemotherapy and immunotherapy to see if the combination can improve outcomes.
Jinan, ShandongAges 18–70 - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT05290194RecruitingPhase 2
New metastatic nasopharyngeal cancer trial with radiotherapy and PD-1
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
Zhuhai, GuangdongAges 18–70 - NCT05892354Recruiting
Immunonutrition to reduce mouth sores after cancer treatment
This trial studies whether special nutritional supplements (immunonutrients) can reduce painful mouth sores (oral mucositis) in people with nasopharyngeal cancer after chemoradiotherapy. If you qualify, you’ll be followed with visits and lab tests to see if the supplements improve comfort and recovery.
Fuzhou, FujianAges 18–70 - NCT06170021Recruiting
Radiation ear problems in throat cancer patients
This study looks at how often radiation therapy for throat cancer causes middle ear infections or fluid buildup. It aims to understand and track these ear problems in patients getting a precise type of radiation called IMRT.
Guangzhou, GuangdongAges 18–70 - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT04085900Recruiting
Screening test for nasopharyngeal cancer blood markers
This study screens people in certain cities to see whether signs in the blood related to a virus (EBV) can help find nasopharyngeal cancer earlier. It may help identify higher-risk people so they can be checked sooner.
Zhongshan, GuangdongAges 30–69 - NCT05517135Recruiting
Personalized treatment for EBV-positive nasopharyngeal cancer
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
SingaporeAges 21–99 - NCT07328841RecruitingPhase 3
Lower radiation dose study for advanced nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07070479RecruitingPhase 2
Combination treatment for PD-1 resistant nasopharyngeal cancer
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Guangzhou, GuangdongAges 18–70
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 168 recruiting nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Nasopharyngeal Carcinoma (NPC)
- Locally Advanced Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8
- Metastatic Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma AJCC v8
- Nasopharyngeal Carcinoma by AJCC V8 Stage
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.